{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:14:22Z","timestamp":1769156062811,"version":"3.49.0"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund Bei aggressiver posteriorer Fr\u00fchgeborenenretinopathie (APROP) k\u00f6nnen Rezidive nach intravitrealer Injektion von Bevacizumab (IVB) trotz erfolgreicher Aktivit\u00e4tskontrolle des Akutstadiums auftreten und erfordern daher langfristige Kontrolluntersuchungen bei Extremfr\u00fchgeborenen. Als Rezidiv wird das Wiederauftreten von Pluszeichen und Leckage (mit oder ohne Proliferation) posterior, an und anterior der Vaskularisationsgrenze definiert.<\/jats:p><jats:p>\n          Methoden RetCam-Weitwinkelfotografien und Fluoreszenzangiografien erfolgten bei Therapiebeginn mit IVB (Bevacizumab 0,312\u2009mg in 0,025\u2009ml pro Auge), vor jeder weiteren Therapie (IVB, Laser- oder Kryokoagulation, Pars-plana-Vitrektomie) sowie am Therapieende. Es wurde das Bildmaterial von 18 Augen\/9 Extremfr\u00fchgeborenen mit APROP die zwischen 08\/2008 und 12\/2017 behandelt wurden (GA 21\u200a\u2013\u200a27 Wochen, GG 430\u200a\u2013\u200a890\u2009g) ausgewertet.<\/jats:p><jats:p>\n          Ergebnisse Mit einer einmaligen Injektion konnte nur bei 4\u00a0Augen\/2 Kindern (22%) ein langfristiger Therapieerfolg erreicht werden. In 2 Augen\/2 Kindern (11%) wurde bei nicht ausreichendem Therapieeffekt eine 2. und 3. Injektion innerhalb von 2 Wochen durchgef\u00fchrt. Bis zu 3 Injektionen zusammen mit einer Laserkoagulation waren in 12 Augen\/6 Kindern (67%) erforderlich, um eine vollst\u00e4ndige R\u00fcckbildung der ROP-Aktivit\u00e4t zu erreichen. In 6 Augen\/3 Kindern (33%) konnte erst mit der Laserkoagulation eine R\u00fcckbildung der Leckage an der urspr\u00fcnglichen Vaskularisationsgrenze erreicht werden. In einem einzigen Auge kam es trotz allem zu einer Netzhautverziehung mit konsekutiver frustraner Netzhautchirurgie. Vor IVB war die Leckage in \u2154 auf Proliferationen zur\u00fcckzuf\u00fchren (12 Augen\/6 Kinder). Bei Rezidiven nach IVB zeigte sich eine Verschiebung des Leckageortes nach posterior (14\u00a0Augen\/4 Kinder), w\u00e4hrend nach Laserkoagulation Leckagen durch Proliferationen auch anterior der\n\t\t\t\t\tVaskularisationsgrenze beobachtet wurden (5 Augen\/3 Kinder). Eine Therapieindikation bei fehlenden Pluszeichen und nicht erkennbaren Proliferationen in der Weitwinkelfotografie ergab sich bei 14 Augen\/4 Kindern aufgrund von angiografischen Aktivit\u00e4tszeichen.<\/jats:p><jats:p>\n          Schlussfolgerungen Die intravitreale Injektion von 0,312\u2009mg Bevacizumab zeigte sich als effektive Behandlungsmethode des APROP-Akutstadiums. Der langfristige Therapieerfolg erforderte die konsequente Erfassung und Behandlung von APROP-Rezidiven. Besonders hilfreich war dabei die Fluoreszenzangiografie in der Diagnostik von nicht erkennbaren Rezidiven in der Weitwinkelfotografie.<\/jats:p>","DOI":"10.1055\/a-1012-1999","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:23:32Z","timestamp":1574814212000},"page":"1468-1476","source":"Crossref","is-referenced-by-count":10,"title":["Fluoreszenzangiografieassistiertes Management von Rezidiven bei aggressiver posteriorer Fr\u00fchgeborenenretinopathie (APROP) nach intravitrealer Monotherapie mit 0,312\u2009mg Bevacizumab"],"prefix":"10.1055","volume":"237","author":[{"given":"Monika","family":"Andrassi-Darida","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Standort Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mais","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Standort Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Stieger","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Standort Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Standort Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312\u2009mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"B Lorenz","year":"2017","journal-title":"Retina"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity. A report by the American Academy of Ophthalmology","volume":"124","author":"D K VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjophthalmol-2015-307263","article-title":"Five years of treatment for retinopathy of prematurity in Sweden. Results from SWEDROP, a national quality register","volume":"100","author":"G Holmstr\u00f6m","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1213\/ANE.0000000000000705","article-title":"Outcomes of extremely premature infants","volume":"120","author":"H Glass","year":"2015","journal-title":"Anesth Analg"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"J T Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"ref7","first-page":"1217","article-title":"Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis","volume":"41","author":"S Hughes","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17469899.2015.1007128","article-title":"Retinopathy of prematurity \u2013 recent developments in diagnosis and treatment \u2013 a review","volume":"10","author":"B Lorenz","year":"2015","journal-title":"Expert Rev Ophthalmol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30 (4 Suppl.)","author":"K A Drenser","year":"2010","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"D J Gunn","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOP.0b013e32832925f9","article-title":"Antivascular endothelial growth factor for retinopathy of prematurity","volume":"21","author":"H A Mintz-Hittner","year":"2009","journal-title":"Curr Opin Pediatr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"R Axer-Siegel","year":"2011","journal-title":"Retina"},{"issue":"S 03","key":"ref13","first-page":"S15","article-title":"Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP)","volume":"94","author":"B Wutthiworawong","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","article-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?","volume":"91","author":"U Spandau","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajoc.2018.05.006","article-title":"Favorable outcomes of adequate laser photocoagulation and salvage bevacizumab treatment for aggressive posterior retinopathy of prematurity","volume":"11","author":"Y Fukushima","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5935\/0004-2749.20180005","article-title":"Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?","volume":"81","author":"S Dikci","year":"2018","journal-title":"Arq Bras Oftalmol"},{"key":"ref17","first-page":"5029278","article-title":"Combination of intravitreal injection of ranibizumab and photocoagulation for the treatment of aggressive posterior retinopathy of prematurity with vitreous hemorrhage","volume":"2016","author":"Y Xu","year":"2016","journal-title":"J Ophthalmol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity following intravitreal bevacizumab monotherapy","volume":"123","author":"H A Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/IAE.0000000000001779","article-title":"Atypical form of retinopathy of prematurity with severe fibrovascular proliferation in the optic disc region","volume":"38","author":"T Yokoi","year":"2017","journal-title":"Retina"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ophtha.2009.01.038","article-title":"Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography","volume":"116","author":"T Yokoi","year":"2009","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3341\/kjo.2013.27.2.109","article-title":"Capillary-free vascularised retina in patients with aggressive posterior retinopathy of prematurity and late retinal capillary formation","volume":"27","author":"S J Ahn","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"J M Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00347-008-1841-9","article-title":"Leitlinie zur augen\u00e4rztlichen Screening-Untersuchung von Fr\u00fchgeborenen","volume":"105","author":"C Jandeck","year":"2008","journal-title":"Ophthalmologe"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"H A Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type 1 prethreshold, threshold, and aggressive posterior retinopathy-27 months follow-up results from Turkey","volume":"253","author":"H Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ophtha.2010.04.021","article-title":"Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity","volume":"118","author":"D Lepore","year":"2011","journal-title":"Ophthalmology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"D Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/aos.12461","article-title":"Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies","volume":"92","author":"S W Park","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ophtha.2015.04.023","article-title":"Influence of fluorescein angiography in the diagnosis and management of retinopathy of prematurity","volume":"122","author":"M A Klufas","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1012-1999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T23:42:01Z","timestamp":1607384521000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1012-1999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1012-1999","relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]}}}